New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 ...

A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of ...
Le Lézard

Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)

New long-term data from Eli Lilly and Company showed Omvoh (mirikizumab-mrkz) delivered durable efficacy through three years in adults with moderately to severely active Crohn's disease.1 These data ...
PharmiWeb

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Co…

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate ...
Medindia

Zenocutuzumab Treatment Beyond Progression Demonstrates Continued Benefit in Patients with NRG1+ Non-Small Cell Lung Cancer: New Results from the eNRGy Trial

(PTx) announced findings from a post hoc analysis of the eNRGy trial (NCT02912949) evaluating treatment beyond progression with zenocutuzumab in patients with advanced neuregulin 1 fusion-positive ...

Universal vaccine to treat colds, flu and COVID developed, and a new study suggests it just might work

Vaccines have traditionally worked by teaching the immune system to recognize a specific virus or bacterium—in effect, ...
PharmiWeb

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as ...
Le Lézard

RYBREVANT FASPROtm (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or ...

Johnson & Johnson today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination ...

Johnson & Johnson: RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line ...

Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO; results surpass current standards of care RARITAN, N.J., Feb. 19 ...

Johnson & Johnson: RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO beyond lung ...
Science Daily

Scientists create universal nasal spray vaccine that protects against COVID, flu, and pneumonia

Scientists at Stanford Medicine have unveiled a bold new kind of “universal” vaccine that could one day protect against everything from COVID-19 and the flu to bacterial pneumonia and even common ...

Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers

Detailed price information for Fennec Pharmaceuticals Inc (FENC-Q) from The Globe and Mail including charting and trades.
Healio

5-year-old girl with persistent hemorrhagic rash

In 1996, a previously healthy 5-year-old girl presented to a local urgent care clinic with a 3-day history of fever and a progressive, generalized vesicular rash, diagnosed as varicella with a known ...